South Wales, Feb. 20 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "POLYNAUT" on Feb. 3. The details about the trademark application no. UK00004334425 published in the journal no. 2026/008 (Feb. 20).
With Stratagem Intellectual Property Management Limited as representative, VIANAUTIS BIO LIMITED filed the trademark application for the below mentioned good(s)/service(s).
Class 1 : Chemicals used in science; chemicals for encapsulating, microencapsulating and decapsulating other chemicals; chemicals for the protection, delivery, transport and triggered or controlled release of other chemicals; chemicals for encapsulating, microencapsulating and decapsulating biologically active ingredients including enzymes and cells; reagents and diagnostic preparations for scientific or medical research use, and clinical or medical laboratory use; targeted diagnostic preparations for scientific or medical research use, and clinical or medical laboratory use.
Class 5 : Pharmaceutical preparations; Pharmaceutical preparations for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; reagents, diagnostics, prophylactics and therapeutic preparations for use in conditions of the central and peripheral nervous systems, immune system and diseases of the lung, kidney, liver or any peripheral organs, and oncology;
vaccines; therapeutic preparations for use in treating diseases of the central and peripheral nervous systems, immune system and diseases of lung, kidney, liver or other organs, and cancer in medical and veterinary patients; targeted preparations for treating diseases of the central and peripheral nervous systems, immune system and diseases of lung, kidney, liver or other organs, or cancer; medical and veterinary preparations for use in for use in central and peripheral nervous system diseases, immune system, diseases, diseases of the lung, kidney, liver and other organs, and cancer; medical and veterinary preparations for the delivery of compounds to the brain for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for crossing the blood-brain barrier for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders; medical and veterinary preparations for delivering reagents, diagnostics, prophylactics and therapeutics across the blood-brain barrier for the treatment and prevention of infectious, autoimmune, viral, metabolic, musculoskeletal, cardiovascular, genitourinary, central nervous system, endocrinological, immunological, obstetrical, gynaecological, oncological, respiratory, neurological, gastrointestinal, hormonal, dermatological and psychiatric diseases and disorders.
Class 42 : Scientific and technological services, namely, scientific research, analysis, testing and development in the field of delivering therapeutics, drug delivery technologies and medicines and research and design relating thereto; industrial analysis and research services in the field of therapeutics, drug delivery technologies and medicines; research and development in the field of encapsulating, microencapsulating and decapsulating chemicals and biologicals for delivery into human or animal cells; medical and veterinary research services; scientific research in the development of new therapies and new methods for delivering therapies; scientific research into nanoparticles; scientific research into encapsulation, microencapsulation and de-capsulation of reagents, diagnostics, prophylactics and therapeutics; scientific research into crossing the blood brain barrier and other biological barriers; scientific research into nano-engineering for intracellular delivery; platform as a service (PAAS) featuring computer software platforms for developing drug delivery products to deliver genetic materials with precise targeting of specific tissues and cell types; platform as a service (PAAS) featuring computer software platforms for research and development of genetic medicine delivery; consultancy relating to all the aforesaid services.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004334425
Disclaimer: Curated by HT Syndication.
